Eli Lilly and Company (LLY) 73.95 $LLY
Incyte's Jakafi Positive in Phase III for Polycythemia Study
Zacks Equity Research - Zacks Investment Research - Fri Jun 10, 8:15AM CDT
Incyte (INCY) announced new 28-week data from the phase III RESPONSE-2 study on Jakafi for the treatment of polycythemia vera.
INCY: 80.41 (-1.20), ABBV: 61.00 (+0.25), LLY: 73.95 (-0.48), BMY: 72.65 (-0.08)
Global Migraine Market Report: 2016 Edition Featuring Amgen, Teva Pharmaceuticals, Eli Lilly and Company & AstraZeneca - Research and Markets
BusinessWire - Fri Jun 10, 4:14AM CDT
Research and Markets has announced the addition of the "Global Migraine Market Report: 2016 Edition" report to their offering.
AMGN: 154.78 (-2.00), LLY: 73.95 (-0.48)
Data in The Lancet Show Olaratumab Plus Doxorubicin Offered 11.8-Month Increase in Overall Survival in Patients with Advanced Soft Tissue Sarcoma, as Reported by Lilly and Memorial Sloan Kettering Researchers
PR Newswire - Thu Jun 09, 5:30PM CDT
Eli Lilly and Company (NYSE: LLY) announced that The Lancet published detailed results from a Phase 2 study evaluating the efficacy and safety of olaratumab, an investigational compound, in combination with doxorubicin chemotherapy in patients with advanced soft tissue sarcoma (STS) not amenable to curative treatment with radiotherapy or surgery. STS is a rare cancer for which patients have limited treatment options. The study met its primary endpoint of progression-free survival (PFS) and showed a statistically significant improvement in overall survival (OS), a key secondary endpoint.
LLY: 73.95 (-0.48)
Lilly and American Migraine Foundation Announce $1 Million Grant for Launch of First Patient Registry to Advance Research and Development in Migraine
PR Newswire - Thu Jun 09, 11:00AM CDT
Eli Lilly and Company (NYSE: LLY) and the American Migraine Foundation announced today that Lilly will provide a $1 million grant to the American Migraine Foundation to sponsor the development of the American Registry for Migraine Research (ARMR), a large-scale, publicly-accessible headache registry and biological repository that will contain clinical, biologic and neuroimaging data to further advance the research and discovery of new treatments for migraine.
LLY: 73.95 (-0.48)
Baricitinib significantly reduces joint damage progression in rheumatoid arthritis in patients who do not respond to conventional DMARDs
CNW Group - Thu Jun 09, 5:45AM CDT
Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) today announced that data from a pivotal long-term extension study, RA-BEYOND, was presented at the Annual European Congress of Rheumatology (EULAR 2016) in London. The findings demonstrate that baricitinib was superior to placebo at inhibiting progressive radiographic joint damage in patients with rheumatoid arthritis (RA).
INCY: 80.41 (-1.20), LLY: 73.95 (-0.48)
Patient-reported outcomes across phase 3 studies of baricitinib demonstrate statistically significant improvements in physical function and quality of life symptoms in patients with rheumatoid arthritis (RA)
CNW Group - Thu Jun 09, 5:45AM CDT
Pivotal trials show treatment with baricitinib resulted in significant improvements in pain, fatigue and ability to perform daily activities compared to methotrexate - the current standard of care - and adalimumab (Humira(®))*
INCY: 80.41 (-1.20), LLY: 73.95 (-0.48)
Studies Demonstrate Lilly's Taltz® (ixekizumab) Maintained or Achieved High Levels of Skin Clearance for Patients with Moderate-to-Severe Plaque Psoriasis through 60 Weeks: Results Published in the New England Journal of Medicine
CNW Group - Wed Jun 08, 4:00PM CDT
Eli Lilly and Company (NYSE: LLY) announced today that the New England Journal of Medicine has published detailed results from three pivotal Phase 3 studies--UNCOVER-1, UNCOVER-2 and UNCOVER-3--that demonstrated the efficacy and safety of Taltz(®) (ixekizumab) through 60 weeks in patients with moderate-to-severe plaque psoriasis. This publication also detailed 12-week efficacy data for patients treated with Taltz in UNCOVER-1.
LLY: 73.95 (-0.48)
Fujitsu and Box Sign MoU for Strategic Content Management Partnership
JCN Newswire - Wed Jun 08, 4:48AM CDT
BOX: 11.24 (-0.58), LLY: 73.95 (-0.48)
Incyte Reports Five-Year Data from Phase III Study on Jakafi
Zacks Equity Research - Zacks Investment Research - Tue Jun 07, 8:45AM CDT
Incyte (INCY) announced five-year data from a phase III study on Jakafi for the treatment of patients with intermediate-2 or high-risk myelofibrosis.
INCY: 80.41 (-1.20), LLY: 73.95 (-0.48), BMY: 72.65 (-0.08), NVS: 78.94 (-1.57)
Results of Clinical and Patient-Reported Outcomes Data for Baricitinib in Patients with Rheumatoid Arthritis to be Presented at Annual European Congress of Rheumatology (EULAR 2016)
PR Newswire - Tue Jun 07, 6:00AM CDT
Lilly immunology portfolio to be featured in 16 presentations
LLY: 73.95 (-0.48)
Acurian Receives 2016 Lilly Global Supplier Award
BusinessWire - Mon Jun 06, 9:47AM CDT
Acurian Inc., a leading, full-service provider of global patient enrollment and retention solutions and a subsidiary of PPD, was selected by Eli Lilly and Company (NYSE: LLY) for its 2016 Lilly Global Supplier Award. Lilly presented the award to Acurian in a ceremony at the company's headquarters in Indianapolis on May 12.
LLY: 73.95 (-0.48)
Whitehouse Laboratories Returns To MD&M East And Participates In USP 661 Panel
PRWeb - Mon Jun 06, 2:22AM CDT
Whitehouse Laboratories is excited to announce that it has accepted an invitation to participate on a USP 661 Panel discussion at MD&M East. The panel discussion, titled "Putting the Changing USP Packaging Chapters to Work" will follow the formal session. Both the session and the panel discussion will address key issues regarding USP Container testing and the impact of recent revisions and pending changes to USP chapters on the industry. Key participants include moderator Dwain L. Sparks, a Strategic Advisor and Expert Consultant, YourEncore (Eli Lilly and Company retiree), Brandon Zurawlow, CCIT Associate Director, Whitehouse Laboratories and Dan Malinowski - Senior Director Package Technology & Innovation Pfizer. The session is being held June 16 at the EastPack Pharmaceutical and Medical Packaging conference (co-located with MD&M East).
LLY: 73.95 (-0.48)
Early-Phase Immuno-Oncology Studies of Lilly's ALIMTA® (pemetrexed) and CYRAMZA® (ramucirumab) with Merck's KEYTRUDA® (pembrolizumab) Show Encouraging Results in Non-Small Cell Lung Cancer
PR Newswire - Sun Jun 05, 8:00AM CDT
Eli Lilly and Company (NYSE: LLY) today announced that clinical study data from two of its ongoing immuno-oncology clinical collaborations with Merck (known as MSD outside the U.S. and Canada) were presented this weekend at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO). Specifically, data were presented from two early-phase trials evaluating ALIMTA® (pemetrexed)-plus-carboplatin and CYRAMZA® (ramucirumab), respectively, in combination with Merck's KEYTRUDA® (pembrolizumab), in patients with non-small cell lung cancer (NSCLC).
LLY: 73.95 (-0.48)
Lilly Announces Results from MONARCH 1 Trial of Abemaciclib Monotherapy
PR Newswire - Fri Jun 03, 4:39PM CDT
Eli Lilly and Company (NYSE: LLY) today announced results from the MONARCH 1 Phase 2 study of abemaciclib, a cyclin-dependent kinase (CDK) 4 and CDK 6 inhibitor, in patients with hormone-receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer. The data, which were presented at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting by Maura Dickler, M.D., of Memorial Sloan Kettering Cancer Center, showed that single-agent activity was observed in metastatic breast cancer patients, for whom endocrine therapy was no longer a suitable treatment option. The MONARCH 1 results (abstract #510) confirmed objective response (ORR), durability of response (DoR), clinical benefit rate (CBR) and progression-free survival (PFS).
LLY: 73.95 (-0.48)
Lilly Announces Diabetes Commercial Update Investor Call
PR Newswire - Wed Jun 01, 1:00PM CDT
Eli Lilly and Company (NYSE: LLY) will conduct a call on June 17 to update the investment community and media on the key commercial aspects of the company's diabetes business. The webcast will begin at 9 a.m. EDT.
LLY: 73.95 (-0.48)
Lilly Announces Webcast to Discuss Abemaciclib Data
PR Newswire - Tue May 31, 1:00PM CDT
Eli Lilly and Company (NYSE: LLY) will conduct a webcast on June 9 to discuss the abemaciclib data presented at the American Society of Clinical Oncology (ASCO) Annual Meeting. The webcast will begin at 10 a.m. EDT.
LLY: 73.95 (-0.48)
Incyte's Jakafi Positive in Phase III for Polycythemia Study
Zacks Equity Research - Zacks Investment Research - Fri Jun 10, 8:15AM CDT
Incyte (INCY) announced new 28-week data from the phase III RESPONSE-2 study on Jakafi for the treatment of polycythemia vera.
INCY: 80.41 (-1.20), ABBV: 61.00 (+0.25), LLY: 73.95 (-0.48), BMY: 72.65 (-0.08)
Global Migraine Market Report: 2016 Edition Featuring Amgen, Teva Pharmaceuticals, Eli Lilly and Company & AstraZeneca - Research and Markets
BusinessWire - Fri Jun 10, 4:14AM CDT
Research and Markets has announced the addition of the "Global Migraine Market Report: 2016 Edition" report to their offering.
AMGN: 154.78 (-2.00), LLY: 73.95 (-0.48)
Data in The Lancet Show Olaratumab Plus Doxorubicin Offered 11.8-Month Increase in Overall Survival in Patients with Advanced Soft Tissue Sarcoma, as Reported by Lilly and Memorial Sloan Kettering Researchers
PR Newswire - Thu Jun 09, 5:30PM CDT
Eli Lilly and Company (NYSE: LLY) announced that The Lancet published detailed results from a Phase 2 study evaluating the efficacy and safety of olaratumab, an investigational compound, in combination with doxorubicin chemotherapy in patients with advanced soft tissue sarcoma (STS) not amenable to curative treatment with radiotherapy or surgery. STS is a rare cancer for which patients have limited treatment options. The study met its primary endpoint of progression-free survival (PFS) and showed a statistically significant improvement in overall survival (OS), a key secondary endpoint.
LLY: 73.95 (-0.48)
Lilly and American Migraine Foundation Announce $1 Million Grant for Launch of First Patient Registry to Advance Research and Development in Migraine
PR Newswire - Thu Jun 09, 11:00AM CDT
Eli Lilly and Company (NYSE: LLY) and the American Migraine Foundation announced today that Lilly will provide a $1 million grant to the American Migraine Foundation to sponsor the development of the American Registry for Migraine Research (ARMR), a large-scale, publicly-accessible headache registry and biological repository that will contain clinical, biologic and neuroimaging data to further advance the research and discovery of new treatments for migraine.
LLY: 73.95 (-0.48)
Baricitinib significantly reduces joint damage progression in rheumatoid arthritis in patients who do not respond to conventional DMARDs
CNW Group - Thu Jun 09, 5:45AM CDT
Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) today announced that data from a pivotal long-term extension study, RA-BEYOND, was presented at the Annual European Congress of Rheumatology (EULAR 2016) in London. The findings demonstrate that baricitinib was superior to placebo at inhibiting progressive radiographic joint damage in patients with rheumatoid arthritis (RA).
INCY: 80.41 (-1.20), LLY: 73.95 (-0.48)
Patient-reported outcomes across phase 3 studies of baricitinib demonstrate statistically significant improvements in physical function and quality of life symptoms in patients with rheumatoid arthritis (RA)
CNW Group - Thu Jun 09, 5:45AM CDT
Pivotal trials show treatment with baricitinib resulted in significant improvements in pain, fatigue and ability to perform daily activities compared to methotrexate - the current standard of care - and adalimumab (Humira(®))*
INCY: 80.41 (-1.20), LLY: 73.95 (-0.48)
Studies Demonstrate Lilly's Taltz® (ixekizumab) Maintained or Achieved High Levels of Skin Clearance for Patients with Moderate-to-Severe Plaque Psoriasis through 60 Weeks: Results Published in the New England Journal of Medicine
CNW Group - Wed Jun 08, 4:00PM CDT
Eli Lilly and Company (NYSE: LLY) announced today that the New England Journal of Medicine has published detailed results from three pivotal Phase 3 studies--UNCOVER-1, UNCOVER-2 and UNCOVER-3--that demonstrated the efficacy and safety of Taltz(®) (ixekizumab) through 60 weeks in patients with moderate-to-severe plaque psoriasis. This publication also detailed 12-week efficacy data for patients treated with Taltz in UNCOVER-1.
LLY: 73.95 (-0.48)
Fujitsu and Box Sign MoU for Strategic Content Management Partnership
JCN Newswire - Wed Jun 08, 4:48AM CDT
BOX: 11.24 (-0.58), LLY: 73.95 (-0.48)
Incyte Reports Five-Year Data from Phase III Study on Jakafi
Zacks Equity Research - Zacks Investment Research - Tue Jun 07, 8:45AM CDT
Incyte (INCY) announced five-year data from a phase III study on Jakafi for the treatment of patients with intermediate-2 or high-risk myelofibrosis.
INCY: 80.41 (-1.20), LLY: 73.95 (-0.48), BMY: 72.65 (-0.08), NVS: 78.94 (-1.57)
Results of Clinical and Patient-Reported Outcomes Data for Baricitinib in Patients with Rheumatoid Arthritis to be Presented at Annual European Congress of Rheumatology (EULAR 2016)
PR Newswire - Tue Jun 07, 6:00AM CDT
Lilly immunology portfolio to be featured in 16 presentations
LLY: 73.95 (-0.48)
Acurian Receives 2016 Lilly Global Supplier Award
BusinessWire - Mon Jun 06, 9:47AM CDT
Acurian Inc., a leading, full-service provider of global patient enrollment and retention solutions and a subsidiary of PPD, was selected by Eli Lilly and Company (NYSE: LLY) for its 2016 Lilly Global Supplier Award. Lilly presented the award to Acurian in a ceremony at the company's headquarters in Indianapolis on May 12.
LLY: 73.95 (-0.48)
Whitehouse Laboratories Returns To MD&M East And Participates In USP 661 Panel
PRWeb - Mon Jun 06, 2:22AM CDT
Whitehouse Laboratories is excited to announce that it has accepted an invitation to participate on a USP 661 Panel discussion at MD&M East. The panel discussion, titled "Putting the Changing USP Packaging Chapters to Work" will follow the formal session. Both the session and the panel discussion will address key issues regarding USP Container testing and the impact of recent revisions and pending changes to USP chapters on the industry. Key participants include moderator Dwain L. Sparks, a Strategic Advisor and Expert Consultant, YourEncore (Eli Lilly and Company retiree), Brandon Zurawlow, CCIT Associate Director, Whitehouse Laboratories and Dan Malinowski - Senior Director Package Technology & Innovation Pfizer. The session is being held June 16 at the EastPack Pharmaceutical and Medical Packaging conference (co-located with MD&M East).
LLY: 73.95 (-0.48)
Early-Phase Immuno-Oncology Studies of Lilly's ALIMTA® (pemetrexed) and CYRAMZA® (ramucirumab) with Merck's KEYTRUDA® (pembrolizumab) Show Encouraging Results in Non-Small Cell Lung Cancer
PR Newswire - Sun Jun 05, 8:00AM CDT
Eli Lilly and Company (NYSE: LLY) today announced that clinical study data from two of its ongoing immuno-oncology clinical collaborations with Merck (known as MSD outside the U.S. and Canada) were presented this weekend at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO). Specifically, data were presented from two early-phase trials evaluating ALIMTA® (pemetrexed)-plus-carboplatin and CYRAMZA® (ramucirumab), respectively, in combination with Merck's KEYTRUDA® (pembrolizumab), in patients with non-small cell lung cancer (NSCLC).
LLY: 73.95 (-0.48)
Lilly Announces Results from MONARCH 1 Trial of Abemaciclib Monotherapy
PR Newswire - Fri Jun 03, 4:39PM CDT
Eli Lilly and Company (NYSE: LLY) today announced results from the MONARCH 1 Phase 2 study of abemaciclib, a cyclin-dependent kinase (CDK) 4 and CDK 6 inhibitor, in patients with hormone-receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer. The data, which were presented at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting by Maura Dickler, M.D., of Memorial Sloan Kettering Cancer Center, showed that single-agent activity was observed in metastatic breast cancer patients, for whom endocrine therapy was no longer a suitable treatment option. The MONARCH 1 results (abstract #510) confirmed objective response (ORR), durability of response (DoR), clinical benefit rate (CBR) and progression-free survival (PFS).
LLY: 73.95 (-0.48)
Lilly Announces Diabetes Commercial Update Investor Call
PR Newswire - Wed Jun 01, 1:00PM CDT
Eli Lilly and Company (NYSE: LLY) will conduct a call on June 17 to update the investment community and media on the key commercial aspects of the company's diabetes business. The webcast will begin at 9 a.m. EDT.
LLY: 73.95 (-0.48)
Lilly Announces Webcast to Discuss Abemaciclib Data
PR Newswire - Tue May 31, 1:00PM CDT
Eli Lilly and Company (NYSE: LLY) will conduct a webcast on June 9 to discuss the abemaciclib data presented at the American Society of Clinical Oncology (ASCO) Annual Meeting. The webcast will begin at 10 a.m. EDT.
LLY: 73.95 (-0.48)
